HEALTHCARE

07 Jun 2016

TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER

Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier


AstraZeneca today announced clinical and safety data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease, a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC),1 where cancer cells spread to the cerebrospinal"......

Continue Reading

02 Jun 2016

Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib

  • Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a monotherapy and in several combination studies
  • Olmutinib will be studied in combination with the immuno-oncology therapy Keytruda®+, second-generation TKI Giotrif®/Gilotrif®**, anti-angiogenic agents Vargatef®***"...

    Continue Reading

01 Jun 2016

Quintiles Introduces Precision Enrollment to Enhance Patient Recruitment in Oncology Trials

Quintiles, the world’s largest provider of product development and integrated healthcare services, today announced its Precision Enrollment offering. The new enrollment model is designed to significantly accelerate site start-up and patient recruitment in oncology clinical trials"...

Continue Reading

01 Jun 2016

Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine is Very Proud to Announce That Institut Curie, France Has Joined Its Consortium

“We are very proud to welcome Institut Curie to WIN,” said Dr. John Mendelsohn, Chairman of WIN and Director of the Khalifa Institute for Personalized Cancer Therapy and past President of MD Anderson Cancer Center. “The Institut Curie is undeniably a leading European cancer"...

Continue Reading

31 May 2016

In Egypt, Novo Nordisk leads the fight in the global war on diabetes

Egypt’s war on diabetes is intensifying. With 7.8 million people suffering from the life-threatening illness, and with that number set to double by 2025, Egypt requires all the industry, doctors, infrastructure, and assistance that can be spared to prevent an epidemic from causing serious"...

Continue Reading

31 May 2016

Health provider Cleopatra’s Egypt IPO 28.6 times oversubscribed

The initial public share offer of Cleopatra Holding, the healthcare arm of the Emirati Abraaj Group, was 28.6 times oversubscribed, the Egyptian stock exchange announced in a statement on Monday.

The demands for the"...

Continue Reading

30 May 2016

Samsung Bioepis Becomes First to Obtain European Commission Approval for Second Anti-TNF-α Biosimilar with Flixabi®

  • Samsung Bioepis solidifies industry leadership in biosimilars by becoming the first company to bring a second anti-TNF-α biosimilar to market
  • Flixabi® is Samsung Bioepis’ second anti-TNF-α biosimilar to receive European Commission approval, following Benepali®, the first-ever etanercept biosimilar in Europe

"...

Continue Reading

30 May 2016

DM Foundation Announces Winners of Aster Media Awards 2016

Sajila Saseendran, Senior Reporter at Khaleej Times and Anand Raj, Features Editor at Gulf News, have been declared joint winners in the International-GCC category of the Aster Media Awards, instituted by the DM Foundation, the philanthropic arm of leading GCC and India private healthcare"...

Continue Reading

29 May 2016

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS® (brentuximab vedotin)"...

Continue Reading

28 May 2016

Takeda Provides Update on EU Marketing Authorization Application for NINLARO® (ixazomib) in Relapsed/Refractory Multiple Myeloma

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending against the authorization of NINLARO® (ixazomib) capsules, an oral proteasome inhibitor for the treatment of patients with relapsed"......

Continue Reading
Found articles: 30 - Pages  « 3 
Contact US | Powered by CNPHUB.com - All Rights Reserved